Todd Cohen, MD, highlights how certain patients with prostate cancer may be able to forgo receipt of combined ADT.
Ehab L. Atallah, MD, discusses the findings of a study which looked at outcomes after TKI cessation in patients with CML.
Laura Chow, MD, FRCPC, discusses the clinical significance of the ASCEND-7 trial, which examined the intracranial effects of ceritinib in ALK-positive NSCLC.
Jeffrey Rubnitz, MD, PhD, discusses a study on the safety and activity of venetoclax plus chemo for young patients with heavily relapsed/refractory AML.
Xue-Zhong Yu, MD, MS, MBA, discusses Sirtuin-1 as a possible therapeutic target for the control of GVHD.
Lori Leslie, MD, discusses clinical outcomes among real-world patients with CLL given first-line therapy with ibrutinib or chemoimmunotherapy (CIT).
Brian Jonas, MD, PhD, discusses the significance of the FDA’s recent approval of venetoclax in combination with azacitidine for the treatment of certain patients with newly diagnosed AML.
Jerry S. H. Lee, PhD, discusses the largest cohort study on real-world outcomes for patients in the Veterans Affairs System treated with ICIs.
Stay in the know.
OncNet Newsletter